Paion is at an advanced stage in developing its ultra-short-acting sedative remimazolam in pivotal US studies in procedural sedation. Paion has launched the Phase III European study in lead indication general anaesthesia, focusing on efficacy and safety vs standard of care. Paion is evaluating its commercial options in the US, Europe and Japan. We have updated our base case assumption, adding milestones for a post-approval deal scenario. This leads us to raise our valuation to €224m from
24 Aug 2015
Remimazolam's commercial prospects in sight
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Remimazolam's commercial prospects in sight
Paion is at an advanced stage in developing its ultra-short-acting sedative remimazolam in pivotal US studies in procedural sedation. Paion has launched the Phase III European study in lead indication general anaesthesia, focusing on efficacy and safety vs standard of care. Paion is evaluating its commercial options in the US, Europe and Japan. We have updated our base case assumption, adding milestones for a post-approval deal scenario. This leads us to raise our valuation to €224m from